News & EventsLearn more about ReForm Biologics and our commitment to innovation in biotherapeutics.
ReForm Biologics Announces New Patent on Surfactant Replacement Excipients to Stabilize Antibody-Based Therapeutics
New surfactant replacement offers a promising alternative to polysorbates for stabilizing proteins
ReForm Biologics and KBI Biopharma Announce Strategic Partnership to Improve Biopharmaceutical Formulations and Development
Collaboration will provide clients competitive advantages, improve speed to market
KBI makes equity investment in ReForm Biologics along with existing investors
ReForm Biologics Secures New Patent Expanding Coverage of Key Excipient Formulation for Antibody-Based Therapeutics
ReForm Biologics, a pharmaceutical technology company developing innovative platforms to improve biologic formulations, expanded its patent portfolio with the issuance of U.S. Patent No. 9,867,881 (the ‘881 patent).
ReForm Biologics Announces Issuance of U.S. Patent for New Excipient to Improve Antibody-Based Therapeutics
ReForm Biologics to present at the 13th annual PEGS Summit
ReForm Biologics, a pharmaceutical technology company developing an innovative platform to improve biologic formulations, announced today the issuance of U.S. patent 9,605,051 (the ‘051 patent) for one of its new excipient formulations.
ReForm Biologics Appoints John M. Sorvillo, Ph.D., as Chief Executive Officer
Dr. Sorvillo brings over 25 years of experience leading the development and licensing of technologies, from discovery platforms and research programs to pre-clinical and clinical products, across a range of therapeutic areas.